Literature DB >> 3535133

New criteria for placement of a prophylactic vena cava filter.

J J Alexander, B L Gewertz, C T Lu, C K Zarins.   

Abstract

In order to identify patients who, having had an initial pulmonary embolism, are likely to develop recurrent emboli despite adequate anticoagulation therapy, ten patients (group 1) with documented recurrent pulmonary embolism during anticoagulation therapy were compared with 31 patients (group 2) who showed no evidence of recurrent emboli during the treatment period. Risk factors for thromboembolic disease were similar between the two groups. Noninvasive venous studies of the lower extremities, including Doppler venous ultrasound and phleborheography (PRG), were performed upon all patients after the initial embolic event. Of the ten patients in group 1, seven (70 per cent) had clinical signs of deep vein thrombosis (DVT). Doppler studies were positive for eight of the nine patients studied, and PRG studies were positive for eight of eight patients tested. In contrast, of the 31 patients who responded well to medical therapy, one patient (3 per cent) had clinical signs of DVT, three patients (10 per cent) had positive Doppler studies and one patient (3 per cent) had a positive PRG. Combined Doppler and PRG studies were positive in 100 per cent of the patients in group 1 but in only 6 per cent of the patients in group 2 (p less than 0.001). The results of this study suggest that patients having an initial pulmonary embolism and DVT of sufficient extent detected by noninvasive studies may be at an increased risk for recurrent PE despite anticoagulation therapy. Insertion of a vena cava filter should be considered in these patients prior to the second embolic event.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3535133

Source DB:  PubMed          Journal:  Surg Gynecol Obstet        ISSN: 0039-6087


  1 in total

1.  The use of inferior vena cava filters in pediatric patients for pulmonary embolus prophylaxis.

Authors:  R A Reed; G P Teitelbaum; P Stanley; M J Mazer; I L Tonkin; N K Rollins
Journal:  Cardiovasc Intervent Radiol       Date:  1996 Nov-Dec       Impact factor: 2.740

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.